The evolution of cyclin dependent kinase inhibitors in the treatment of cancer
Published 2021 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
The evolution of cyclin dependent kinase inhibitors in the treatment of cancer
Authors
Keywords
-
Journal
Expert Review of Anticancer Therapy
Volume 21, Issue 10, Pages 1105-1124
Publisher
Informa UK Limited
Online
2021-06-28
DOI
10.1080/14737140.2021.1944109
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- CCNE1 and BRD4 co-amplification in high-grade serous ovarian cancer is associated with poor clinical outcomes
- (2020) Shariska Petersen et al. GYNECOLOGIC ONCOLOGY
- A phase Ib trial of the cyclin-dependent kinase inhibitor dinaciclib (dina) in combination with pembrolizumab (P) in patients with advanced triple-negative breast cancer (TNBC) and response correlation with MYC-overexpression.
- (2020) Amy Jo Chien et al. JOURNAL OF CLINICAL ONCOLOGY
- PARSIFAL: A randomized, multicenter, open-label, phase II trial to evaluate palbociclib in combination with fulvestrant or letrozole in endocrine-sensitive patients with estrogen receptor (ER)[+]/HER2[-] metastatic breast cancer.
- (2020) Antonio Llombart-Cussac et al. JOURNAL OF CLINICAL ONCOLOGY
- Prognostic impact of ESR1 mutations in ER+ HER2- MBC patients prior treated with first line AI and palbociclib: An exploratory analysis of the PADA-1 trial.
- (2020) Francois Clement Bidard et al. JOURNAL OF CLINICAL ONCOLOGY
- Participation of the ATR/CHK1 pathway in replicative stress targeted therapy of high-grade ovarian cancer
- (2020) Patrycja Gralewska et al. Journal of Hematology & Oncology
- Abemaciclib plus trastuzumab with or without fulvestrant versus trastuzumab plus standard-of-care chemotherapy in women with hormone receptor-positive, HER2-positive advanced breast cancer (monarcHER): a randomised, open-label, phase 2 trial
- (2020) Sara M Tolaney et al. LANCET ONCOLOGY
- The genomic landscape of intrinsic and acquired resistance to cyclin-dependent kinase 4/6 inhibitors in patients with hormone receptor positive metastatic breast cancer
- (2020) Seth A. Wander et al. Cancer Discovery
- Fadraciclib (CYC065), a novel CDK inhibitor, targets key pro-survival and oncogenic pathways in cancer
- (2020) Sheelagh Frame et al. PLoS One
- 273O nextMONARCH: Final overall survival analysis of abemaciclib monotherapy or in combination with tamoxifen in patients with HR+, HER2- metastatic breast cancer
- (2020) E.P. Hamilton et al. ANNALS OF ONCOLOGY
- LBA5_PR Abemaciclib in high risk early breast cancer
- (2020) S.R.D. Johnston et al. ANNALS OF ONCOLOGY
- LBA19 GEICAM/2014-12 (FLIPPER) study: First analysis from a randomized phase II trial of fulvestrant (F)/palbociclib (P) versus (vs) F/placebo (PL) as first-line therapy in postmenopausal women with HR (hormone receptor)+/HER2– endocrine sensitive advanced breast cancer (ABC)
- (2020) J. Albanell et al. ANNALS OF ONCOLOGY
- Phase 1 safety, pharmacokinetic and pharmacodynamic study of fadraciclib (CYC065), a cyclin dependent kinase inhibitor, in patients with advanced cancers (NCT02552953)
- (2020) K.T. Do et al. EUROPEAN JOURNAL OF CANCER
- CCNE1 amplification is associated with poor prognosis in patients with triple negative breast cancer
- (2019) Zi-Ming Zhao et al. BMC CANCER
- Comparative efficacy of palbociclib, ribociclib and abemaciclib for ER+ metastatic breast cancer: an adjusted indirect analysis of randomized controlled trials
- (2019) Fausto Petrelli et al. BREAST CANCER RESEARCH AND TREATMENT
- Retinoblastoma mutation predicts poor outcomes in advanced non small cell lung cancer
- (2019) Priyanka Bhateja et al. Cancer Medicine
- MicroRNA-Mediated Suppression of the TGF-β Pathway Confers Transmissible and Reversible CDK4/6 Inhibitor Resistance
- (2019) Liam Cornell et al. Cell Reports
- Aberrant FGFR signaling mediates resistance to CDK4/6 inhibitors in ER+ breast cancer
- (2019) Luigi Formisano et al. Nature Communications
- Cyclin E1 Expression and Palbociclib Efficacy in Previously Treated Hormone Receptor–Positive Metastatic Breast Cancer
- (2019) Nicholas C. Turner et al. JOURNAL OF CLINICAL ONCOLOGY
- Discovery and characterization of SY-1365, a selective, covalent inhibitor of CDK7
- (2019) Shanhu Hu et al. CANCER RESEARCH
- Ribociclib plus Trastuzumab in Advanced, HER2-positive Breast Cancer: Results of A Phase Ib/II trial
- (2019) Shom Goel et al. Clinical Breast Cancer
- Triplet therapy (continuous ribociclib, everolimus, exemestane) in HR+/HER2− advanced breast cancer postprogression on a CDK4/6 inhibitor (TRINITI-1): Efficacy, safety, and biomarker results.
- (2019) Aditya Bardia et al. JOURNAL OF CLINICAL ONCOLOGY
- Tucatinib, palbociclib, and letrozole in HR+/HER2+ metastatic breast cancer: Report of phase IB safety cohort.
- (2019) Elena Shagisultanova et al. JOURNAL OF CLINICAL ONCOLOGY
- The CHK1 Inhibitor Prexasertib Exhibits Monotherapy Activity in High-Grade Serous Ovarian Cancer Models and Sensitizes to PARP Inhibition
- (2019) Kalindi Parmar et al. CLINICAL CANCER RESEARCH
- Outcomes of Older Women With Hormone Receptor–Positive, Human Epidermal Growth Factor Receptor–Negative Metastatic Breast Cancer Treated With a CDK4/6 Inhibitor and an Aromatase Inhibitor: An FDA Pooled Analysis
- (2019) Lynn J. Howie et al. JOURNAL OF CLINICAL ONCOLOGY
- Venous thromboembolism in breast cancer patients receiving cyclin‐dependent kinase inhibitors
- (2019) Lorenzo Gervaso et al. JOURNAL OF THROMBOSIS AND HAEMOSTASIS
- Trilaciclib plus chemotherapy versus chemotherapy alone in patients with metastatic triple-negative breast cancer: a multicentre, randomised, open-label, phase 2 trial
- (2019) Antoinette R Tan et al. LANCET ONCOLOGY
- Inhibition of the transcriptional kinase CDK7 overcomes therapeutic resistance in HER2-positive breast cancers
- (2019) Bowen Sun et al. ONCOGENE
- The Effect of Abemaciclib Plus Fulvestrant on Overall Survival in Hormone Receptor–Positive, ERBB2-Negative Breast Cancer That Progressed on Endocrine Therapy—MONARCH 2
- (2019) George W. Sledge et al. JAMA Oncology
- Myelopreservation with the CDK4/6 inhibitor trilaciclib in patients with small-cell lung cancer receiving first-line chemotherapy: a phase Ib/randomized phase II trial
- (2019) J M Weiss et al. ANNALS OF ONCOLOGY
- LBA7_PROverall survival (OS) results of the phase III MONALEESA-3 trial of postmenopausal patients (pts) with hormone receptor-positive (HR+), human epidermal growth factor 2-negative (HER2−) advanced breast cancer (ABC) treated with fulvestrant (FUL) ± ribociclib (RIB)
- (2019) D J Slamon et al. ANNALS OF ONCOLOGY
- AZD4573 is a highly selective CDK9 inhibitor that suppresses Mcl-1 and induces apoptosis in hematological cancer cells.
- (2019) Justin Cidado et al. CLINICAL CANCER RESEARCH
- PTEN Loss Mediates Clinical Cross-Resistance to CDK4/6 and PI3Kα Inhibitors in Breast Cancer
- (2019) Carlotta Costa et al. Cancer Discovery
- CDK4/6 inhibitor treatment for patients with hormone receptor-positive, HER2-negative, advanced or metastatic breast cancer: a US Food and Drug Administration pooled analysis
- (2019) Jennifer J Gao et al. LANCET ONCOLOGY
- Updated results from MONALEESA-2, a phase III trial of first-line ribociclib plus letrozole versus placebo plus letrozole in hormone receptor-positive, HER2-negative advanced breast cancer
- (2018) G N Hortobagyi et al. ANNALS OF ONCOLOGY
- An Integrated TCGA Pan-Cancer Clinical Data Resource to Drive High-Quality Survival Outcome Analytics
- (2018) Jianfang Liu et al. CELL
- Oncogenic Signaling Pathways in The Cancer Genome Atlas
- (2018) Francisco Sanchez-Vega et al. CELL
- MAPK Reliance via Acquired CDK4/6 Inhibitor Resistance in Cancer
- (2018) Renée de Leeuw et al. CLINICAL CANCER RESEARCH
- Dinaciclib induces immunogenic cell death and enhances anti-PD1–mediated tumor suppression
- (2018) Dewan Md Sakib Hossain et al. JOURNAL OF CLINICAL INVESTIGATION
- Phase III Randomized Study of Ribociclib and Fulvestrant in Hormone Receptor–Positive, Human Epidermal Growth Factor Receptor 2–Negative Advanced Breast Cancer: MONALEESA-3
- (2018) Dennis J. Slamon et al. JOURNAL OF CLINICAL ONCOLOGY
- Prexasertib, a cell cycle checkpoint kinase 1 and 2 inhibitor, in BRCA wild-type recurrent high-grade serous ovarian cancer: a first-in-class proof-of-concept phase 2 study
- (2018) Jung-Min Lee et al. LANCET ONCOLOGY
- Ribociclib plus endocrine therapy for premenopausal women with hormone-receptor-positive, advanced breast cancer (MONALEESA-7): a randomised phase 3 trial
- (2018) Debu Tripathy et al. LANCET ONCOLOGY
- The CDK4/6 Inhibitor Abemaciclib Induces a T Cell Inflamed Tumor Microenvironment and Enhances the Efficacy of PD-L1 Checkpoint Blockade
- (2018) David A. Schaer et al. Cell Reports
- CDKN2A/P16INK4A variants association with breast cancer and their in-silico analysis
- (2018) Ayesha Aftab et al. Breast Cancer
- The genetic landscape and clonal evolution of breast cancer resistance to palbociclib plus fulvestrant in the PALOMA-3 trial
- (2018) Ben O'Leary et al. Cancer Discovery
- Palbociclib resistance confers dependence on an FGFR-MAP kinase-mTOR-driven pathway in KRAS-mutant non-small cell lung cancer
- (2018) Eric Haines et al. Oncotarget
- Letrozole and palbociclib versus chemotherapy as neoadjuvant therapy of high-risk luminal breast cancer
- (2018) P Cottu et al. ANNALS OF ONCOLOGY
- Loss of the FAT1 Tumor Suppressor Promotes Resistance to CDK4/6 Inhibitors via the Hippo Pathway
- (2018) Zhiqiang Li et al. CANCER CELL
- Abemaciclib inhibits renal tubular secretion without changing glomerular filtration rate
- (2018) Jill C. Chappell et al. CLINICAL PHARMACOLOGY & THERAPEUTICS
- Intestinal Toxicity in Rats Following Administration of CDK4/6 Inhibitors Is Independent of Primary Pharmacology
- (2018) Stephane Thibault et al. MOLECULAR CANCER THERAPEUTICS
- Overall Survival with Palbociclib and Fulvestrant in Advanced Breast Cancer
- (2018) Nicholas C. Turner et al. NEW ENGLAND JOURNAL OF MEDICINE
- Aurora-A kinase inhibition is synthetic lethal with loss of the RB1 tumor suppressor gene
- (2018) Xueqian Gong et al. Cancer Discovery
- MONARCH 2: Abemaciclib in Combination With Fulvestrant in Women With HR+/HER2− Advanced Breast Cancer Who Had Progressed While Receiving Endocrine Therapy
- (2017) George W. Sledge et al. JOURNAL OF CLINICAL ONCOLOGY
- MONARCH 3: Abemaciclib As Initial Therapy for Advanced Breast Cancer
- (2017) Matthew P. Goetz et al. JOURNAL OF CLINICAL ONCOLOGY
- Characterization of Neutropenia in Advanced Cancer Patients Following Palbociclib Treatment Using a Population Pharmacokinetic-Pharmacodynamic Modeling and Simulation Approach
- (2017) Wan Sun et al. JOURNAL OF CLINICAL PHARMACOLOGY
- De novo MYC addiction as an adaptive response of cancer cells to CDK4/6 inhibition
- (2017) Míriam Tarrado‐Castellarnau et al. Molecular Systems Biology
- CDK4/6 inhibition triggers anti-tumour immunity
- (2017) Shom Goel et al. NATURE
- CDK4/6 Inhibition Augments Antitumor Immunity by Enhancing T-cell Activation
- (2017) Jiehui Deng et al. Cancer Discovery
- Preclinical development of G1T38: A novel, potent and selective inhibitor of cyclin dependent kinases 4/6 for use as an oral antineoplastic in patients with CDK4/6 sensitive tumors
- (2017) John E. Bisi et al. Oncotarget
- Preclinical characterization of abemaciclib in hormone receptor positive breast cancer
- (2017) Raquel Torres-Guzmán et al. Oncotarget
- A phase 1 clinical trial of flavopiridol consolidation in chronic lymphocytic leukemia patients following chemoimmunotherapy
- (2016) Farrukh T. Awan et al. ANNALS OF HEMATOLOGY
- biomarkersExploratory biomarkers in MONARCH 1, a phase II study of abemaciclib monotherapy in hormone-receptor positive (HR ) HER2- metastatic breast cancer (MBC)
- (2016) S.M. Tolaney et al. ANNALS OF ONCOLOGY
- Overcoming Therapeutic Resistance in HER2-Positive Breast Cancers with CDK4/6 Inhibitors
- (2016) Shom Goel et al. CANCER CELL
- Early Adaptation and Acquired Resistance to CDK4/6 Inhibition in Estrogen Receptor–Positive Breast Cancer
- (2016) Maria Teresa Herrera-Abreu et al. CANCER RESEARCH
- Overview of CDK9 as a target in cancer research
- (2016) Fatima Morales et al. CELL CYCLE
- Expression of CDK7, Cyclin H, and MAT1 Is Elevated in Breast Cancer and Is Prognostic in Estrogen Receptor-Positive Breast Cancer
- (2016) H. Patel et al. CLINICAL CANCER RESEARCH
- A Phase I Study of the Cyclin-Dependent Kinase 4/6 Inhibitor Ribociclib (LEE011) in Patients with Advanced Solid Tumors and Lymphomas
- (2016) J. R. Infante et al. CLINICAL CANCER RESEARCH
- Fulvestrant 500 mg versus anastrozole 1 mg for hormone receptor-positive advanced breast cancer (FALCON): an international, randomised, double-blind, phase 3 trial
- (2016) John F R Robertson et al. LANCET
- Fulvestrant plus palbociclib versus fulvestrant plus placebo for treatment of hormone-receptor-positive, HER2-negative metastatic breast cancer that progressed on previous endocrine therapy (PALOMA-3): final analysis of the multicentre, double-blind, phase 3 randomised controlled trial
- (2016) Massimo Cristofanilli et al. LANCET ONCOLOGY
- A MYC–aurora kinase A protein complex represents an actionable drug target in p53-altered liver cancer
- (2016) Daniel Dauch et al. NATURE MEDICINE
- Ribociclib as First-Line Therapy for HR-Positive, Advanced Breast Cancer
- (2016) Gabriel N. Hortobagyi et al. NEW ENGLAND JOURNAL OF MEDICINE
- Palbociclib and Letrozole in Advanced Breast Cancer
- (2016) Richard S. Finn et al. NEW ENGLAND JOURNAL OF MEDICINE
- Acquired CDK6 amplification promotes breast cancer resistance to CDK4/6 inhibitors and loss of ER signaling and dependence
- (2016) C Yang et al. ONCOGENE
- Palbociclib in Combination With Fulvestrant in Women With Hormone Receptor-Positive/HER2-Negative Advanced Metastatic Breast Cancer: Detailed Safety Analysis From a Multicenter, Randomized, Placebo-Controlled, Phase III Study (PALOMA-3)
- (2016) Sunil Verma et al. ONCOLOGIST
- Efficacy and Safety of Abemaciclib, an Inhibitor of CDK4 and CDK6, for Patients with Breast Cancer, Non-Small Cell Lung Cancer, and Other Solid Tumors
- (2016) A. Patnaik et al. Cancer Discovery
- Inhibition of cyclin dependent kinase 9 by dinaciclib suppresses cyclin B1 expression and tumor growth in triple negative breast cancer
- (2016) Sandeep Rajput et al. Oncotarget
- Oncogenic regulation of tumor metabolic reprogramming
- (2016) Míriam Tarrado-Castellarnau et al. Oncotarget
- CDK12 Inhibition Reverses De Novo and Acquired PARP Inhibitor Resistance in BRCA Wild-Type and Mutated Models of Triple-Negative Breast Cancer
- (2016) Shawn F. Johnson et al. Cell Reports
- Multinucleation and Mesenchymal-to-Epithelial Transition Alleviate Resistance to Combined Cabazitaxel and Antiandrogen Therapy in Advanced Prostate Cancer
- (2015) S. K. Martin et al. CANCER RESEARCH
- Metabolic Signature Identifies Novel Targets for Drug Resistance in Multiple Myeloma
- (2015) P. Maiso et al. CANCER RESEARCH
- The cyclin-dependent kinase 4/6 inhibitor palbociclib in combination with letrozole versus letrozole alone as first-line treatment of oestrogen receptor-positive, HER2-negative, advanced breast cancer (PALOMA-1/TRIO-18): a randomised phase 2 study
- (2015) Richard S Finn et al. LANCET ONCOLOGY
- Comprehensive genomic profiles of small cell lung cancer
- (2015) Julie George et al. NATURE
- The history and future of targeting cyclin-dependent kinases in cancer therapy
- (2015) Uzma Asghar et al. NATURE REVIEWS DRUG DISCOVERY
- CDK 4/6 Inhibitors Sensitize PIK3CA Mutant Breast Cancer to PI3K Inhibitors
- (2014) Sadhna R. Vora et al. CANCER CELL
- CDK 4/6 Inhibitor Palbociclib (PD0332991) in Rb+ Advanced Breast Cancer: Phase II Activity, Safety, and Predictive Biomarker Assessment
- (2014) A. DeMichele et al. CLINICAL CANCER RESEARCH
- CDK9-mediated transcription elongation is required for MYC addiction in hepatocellular carcinoma
- (2014) Chun-Hao Huang et al. GENES & DEVELOPMENT
- Genetic Characterization of the Role of the Cip/Kip Family of Proteins as Cyclin-Dependent Kinase Inhibitors and Assembly Factors
- (2014) A. Cerqueira et al. MOLECULAR AND CELLULAR BIOLOGY
- Cyclin D activates the Rb tumor suppressor by mono-phosphorylation
- (2014) Anil M Narasimha et al. eLife
- Randomized Phase II Trial of the Cyclin-Dependent Kinase Inhibitor Dinaciclib (MK-7965) Versus Capecitabine in Patients With Advanced Breast Cancer
- (2013) Monica M. Mita et al. Clinical Breast Cancer
- CDKN2A/p16 Inactivation Mechanisms and Their Relationship to Smoke Exposure and Molecular Features in Non–Small-Cell Lung Cancer
- (2013) Kit W. Tam et al. Journal of Thoracic Oncology
- A first-in-human, phase 1, dose-escalation study of dinaciclib, a novel cyclin-dependent kinase inhibitor, administered weekly in subjects with advanced malignancies
- (2013) John J Nemunaitis et al. Journal of Translational Medicine
- Randomized phase 2 study of the cyclin-dependent kinase inhibitor dinaciclib (MK-7965) versus erlotinib in patients with non-small cell lung cancer
- (2013) Joe J. Stephenson et al. LUNG CANCER
- The Molecular Balancing Act of p16 INK4a in Cancer and Aging
- (2013) Kyle M. LaPak et al. MOLECULAR CANCER RESEARCH
- Selective CDK4/6 inhibition with tumor responses by PD0332991 in patients with mantle cell lymphoma
- (2012) J. P. Leonard et al. BLOOD
- An integrated view of cyclin E function and regulation
- (2012) Ka Tat Siu et al. CELL CYCLE
- MYC pathway activation in triple-negative breast cancer is synthetic lethal with CDK inhibition
- (2012) Dai Horiuchi et al. JOURNAL OF EXPERIMENTAL MEDICINE
- Cyclin E2 Overexpression Is Associated with Endocrine Resistance but not Insensitivity to CDK2 Inhibition in Human Breast Cancer Cells
- (2012) C. E. Caldon et al. MOLECULAR CANCER THERAPEUTICS
- BET Bromodomain Inhibition as a Therapeutic Strategy to Target c-Myc
- (2011) Jake E. Delmore et al. CELL
- Inhibition of BET recruitment to chromatin as an effective treatment for MLL-fusion leukaemia
- (2011) Mark A. Dawson et al. NATURE
- Tipping the Balance: Cdk2 Enables Myc to Suppress Senescence
- (2010) P. Hydbring et al. CANCER RESEARCH
- Dinaciclib (SCH 727965), a Novel and Potent Cyclin-Dependent Kinase Inhibitor
- (2010) David Parry et al. MOLECULAR CANCER THERAPEUTICS
- Cdk2 suppresses cellular senescence induced by the c-myc oncogene
- (2009) Stefano Campaner et al. NATURE CELL BIOLOGY
- Phosphorylation by Cdk2 is required for Myc to repress Ras-induced senescence in cotransformation
- (2009) P. Hydbring et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Cyclin A/cdk2 coordinates centrosomal and nuclear mitotic events
- (2008) L De Boer et al. ONCOGENE
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started